Brainsway (NASDAQ:BWAY) Price Target Raised to $19.00 at HC Wainwright

Posted by Brenda Bartman on Aug 31st, 2026

Brainsway (NASDAQ:BWAY – Get Free Report) had its target price hoisted by investment analysts at HC Wainwright from $17.00 to $19.00 in a research report issued to clients and investors on Monday, MarketBeat reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s target price points to a potential upside of 32.87% from the company’s current price.

A number of other equities research analysts have also issued reports on BWAY. LADENBURG THALM/SH SH upped their target price on shares of Brainsway from $18.00 to $18.80 and gave the company a “buy” rating in a research note on Thursday, August 13th. Zacks Research lowered Brainsway from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 11th. Weiss Ratings cut Brainsway from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Wednesday, August 19th. BTIG Research increased their target price on Brainsway from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Finally, New Street Research reiterated a “buy” rating on shares of Brainsway in a research report on Friday, July 24th. Five analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, Brainsway currently has an average rating of “Moderate Buy” and an average target price of $18.20.

Get Our Latest Analysis on BWAY

Brainsway Stock Performance

Brainsway stock opened at $14.30 on Monday. Brainsway has a 52 week low of $7.14 and a 52 week high of $17.40. The stock has a market cap of $574.72 million, a P/E ratio of 32.50 and a beta of 1.24. The stock has a 50 day moving average of $15.21 and a 200-day moving average of $14.61.

Brainsway (NASDAQ:BWAY – Get Free Report) last posted its quarterly earnings results on Wednesday, August 12th. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $0.04. The firm had revenue of $17.11 million for the quarter, compared to analysts’ expectations of $16.54 million. Brainsway had a net margin of 15.65% and a return on equity of 12.74%. As a group, equities analysts predict that Brainsway will post 0.34 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Brainsway

Several institutional investors and hedge funds have recently bought and sold shares of BWAY. Goldman Sachs Group Inc. raised its position in shares of Brainsway by 2.3% during the 4th quarter. Goldman Sachs Group Inc. now owns 25,738 shares of the company’s stock worth $490,000 after purchasing an additional 589 shares during the period. Man Group plc boosted its position in Brainsway by 4.5% during the 4th quarter. Man Group plc now owns 18,027 shares of the company’s stock valued at $343,000 after purchasing an additional 782 shares during the period. NewEdge Advisors LLC grew its stake in Brainsway by 7.4% during the 3rd quarter. NewEdge Advisors LLC now owns 28,629 shares of the company’s stock worth $431,000 after buying an additional 1,964 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. bought a new position in Brainsway during the 1st quarter worth $40,000. Finally, Ballast Advisors LLC acquired a new stake in Brainsway in the first quarter worth $55,000. Institutional investors and hedge funds own 30.11% of the company’s stock.

Brainsway Company Profile

(Get Free Report)

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.